1800 202 8726
Thyroid cytology report

Bethesda Category 4 — Follicular Neoplasm

A Category 4 result on a thyroid biopsy report does not say cancer. It says the biopsy found a type of cell growth that looks the same whether it is benign or malignant — and that the needle biopsy alone cannot tell you which one you have.

Medically reviewed by Dr. Muralidhar Muddusetty, Surgical Oncologist, MBBS (AIIMS) · MS Surgery (AIIMS) · DNB Surg Onc · MRCS (Edinburgh) · Last reviewed September 2026

  • Not a cancer diagnosis — Category 4 is an indeterminate result. The pathologist could not classify the nodule as clearly benign or clearly malignant from the cells alone.
  • The answer requires surgery — Whether the growth has invaded its own capsule — the defining marker of carcinoma — can only be seen in a complete surgical specimen, not in individual cells.
  • Most turn out to be benign — After surgery, the majority of Category 4 nodules prove to be follicular adenomas. The operation is done to find out which category yours belongs to.
  • This is why the system exists — The Bethesda system was designed so that indeterminate results like this one get a clear action pathway rather than a vague 'unable to diagnose'.
4.8 · 800+ Google reviews · 15,000+ patients treated
Limited Slots Today

Get this explained properly

₹950   Today: FREE  ·  Including free written second opinion

Reply within 2 working hours
Report reviewed by a senior oncologist
Confidential. No commitment to start treatment.
or
Call 1800 202 8726
17+
Cancer Specialists
on Panel
96.9%
Breast Cancer
Survival Rate*
15,000+
Patients
Treated
4.8★
Google Rating
(800+ reviews)

Bethesda Category 4 means your thyroid needle biopsy found follicular-patterned cells that could belong to either a benign adenoma or a follicular carcinoma. FNAC alone cannot tell the difference. Most oncologists and endocrinologists recommend surgical removal of the affected lobe so the pathologist can examine the whole tumour under the microscope.

What does Bethesda Category 4 mean on a thyroid report?

Category 4 on a thyroid cytology report means the pathologist found follicular-patterned cells that look identical whether the growth is benign or malignant.

The Bethesda system uses six categories to report thyroid needle biopsies. Category 4 is formally labelled Follicular Neoplasm, or Suspicious for a Follicular Neoplasm.

This is not a cancer diagnosis. It is a statement that the available information — individual cells from a needle — is not enough to answer whether the growth has overstepped its boundary.

The Bethesda System for Reporting Thyroid Cytopathology (2023 edition) reports that roughly one in five to two in five nodules in this category turn out to be malignant after surgical removal. The rest are benign. The biopsy report cannot place your nodule in either group — that is exactly why this category exists.

What will your team look at before recommending next steps?

  • Your ultrasound report — high-risk features such as irregular edges, internal calcification, or a taller-than-wide shape raise the level of concern
  • The size of the nodule — larger nodules carry somewhat higher suspicion
  • Whether the same nodule has grown compared with a previous scan
  • Your age, general health, and fitness for a surgical procedure
  • Whether molecular testing of the biopsy sample is available and likely to change the decision
  • Your own priorities and how you want to weigh uncertainty against the risks and recovery of surgery

Still unclear?

Send your reports across and a specialist will walk you through what they mean — what is known, what is not, and what the options actually are.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Dr. Naresh Gundu
Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile
Dr. C. Raghavendra Reddy
Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile
Dr. Bharati Devi Gorantla
Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile
Dr. Owais Mohammed
Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile
Dr. T. Raghavender Reddy
Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile
Dr. N. Kiranmayee
Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile
Dr. Muralidhar Muddusetty
Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile
Dr. Raghavendra Naik
Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Mohammed  Imaduddin
Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Vinay Mamidala
Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile
Dr. Paila Gowri Naidu
Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile
Dr. Venkata Sushma P
Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile
Dr. Kirti Ranjan Mohanty
Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile
Dr. Gangadhar Vajrala
Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile
Dr. Basudev Pokhrel
Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile
Dr. Mohammed Imran
Interventional Radiologist

Dr. Mohammed Imran

View Profile
Dr. Vajja Sandeep Kumar
Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile
Dr. Sridhar Kamani
Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

Get a straight answer from a specialist

45 minutes, your reports reviewed, your questions answered in plain language.

Book Free Consultation Call 1800 202 8726

Why can a needle biopsy not tell benign from malignant here?

Follicular adenoma and follicular carcinoma look identical at the cell level. Both grow in the same round follicular pattern. Both use the same cell types.

The only difference between them is structural. Follicular carcinoma has broken through its own outer capsule, or it has invaded nearby blood vessels. Follicular adenoma has not.

A needle biopsy collects loose individual cells. It cannot show the intact capsule surrounding the nodule, or whether those vessels have been invaded. That architecture is only visible to a pathologist once the lobe has been surgically removed and prepared as a complete tissue section.

This is a limitation of the technique itself, not a failure of the laboratory or the pathologist who reported your result.

What do the words in this report mean?

Follicular neoplasm
A growth in the thyroid made up of follicular cells arranged in a recognisable pattern. Neoplasm means a new, abnormal growth — it does not by itself mean cancer.
FNAC / FNA
Fine needle aspiration cytology. A thin needle draws out a small number of cells from the nodule. It examines individual cells, not the full tissue structure of the growth.
Follicular adenoma
A benign follicular growth with an intact capsule that has not invaded any blood vessels. Completely contained within its own boundary.
Follicular carcinoma
A malignant follicular growth. Its defining feature is that it has broken through its capsule or invaded blood vessels — something only visible on the full surgical specimen.
Capsular invasion
When tumour cells have broken through the fibrous outer wall of the nodule. This is the key finding that separates follicular carcinoma from adenoma. FNAC cannot assess it.
Lobectomy / hemithyroidectomy
Surgical removal of one lobe of the thyroid. This is the standard diagnostic operation for a Category 4 nodule. It gives the pathologist a complete specimen to examine.
NIFTP
Non-invasive follicular thyroid neoplasm with papillary-like nuclear features. A low-risk borderline tumour. Its reclassification in recent years is one reason malignancy risk figures for Category 4 vary between published sources.

Did you know?

Before the Bethesda system was introduced, thyroid cytology reports used inconsistent language across hospitals, making it impossible to give patients reliable risk figures or a clear next step.

Category 4 was designed specifically to capture the follicular group — cases where the cytology is genuinely indeterminate and surgery is the only path to a definitive answer.

Source: The Bethesda System for Reporting Thyroid Cytopathology, 3rd edition (2023)

Explore 114 more Waiting For and Understanding Your Report topics

HUB — Cytology and Prostate Scoring Systems Explained

HUB — Understanding Your Biopsy Report

HUB — Waiting for Biopsy Results

All Waiting For and Understanding Your Report →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726
Common questions

Frequently asked questions

Does Bethesda Category 4 mean I have thyroid cancer?

No. Category 4 is an indeterminate result, not a cancer diagnosis. It means the cells in your biopsy sample have a follicular arrangement that looks identical whether the growth is benign or malignant. The pathologist is not saying cancer is present — they are saying the biopsy technique cannot answer the question either way. A definitive answer requires examining the full surgical specimen.

What are the chances my nodule is cancerous?

The Bethesda System for Reporting Thyroid Cytopathology (2023 edition) reports that roughly one in five to two in five nodules in this category prove malignant after surgery. This range varies by institution, by ultrasound features, and by how a borderline tumour category called NIFTP is counted. These figures describe populations, not individuals. Your own risk depends on your ultrasound findings, nodule size, and other factors your team will weigh with you.

Will I definitely need surgery?

Surgery is the most common recommendation because it is the only way to get a definitive answer. Some teams will use molecular testing of the biopsy sample first — this can shift the probability enough to support close monitoring instead of immediate surgery in selected cases. The decision depends on your ultrasound findings, nodule size, general health, and your own preferences. Not every Category 4 nodule is managed the same way.

Will I lose my whole thyroid gland?

The standard diagnostic operation for a Category 4 nodule is a lobectomy — removal of one lobe of the thyroid, the half containing the nodule. The other lobe is left in place. If the surgical pathology then confirms carcinoma, a second operation to remove the remaining lobe is sometimes recommended depending on what the specimen shows. Whether you would need that second step is a question best asked after the first specimen has been examined.

Can I repeat the biopsy instead of having surgery?

Repeating the FNAC usually returns the same Category 4 result, because the limitation is not the quality of the original sample — it is what FNAC can and cannot see by its nature. A repeat biopsy is sometimes useful when the first sample was technically inadequate. It does not resolve the benign-versus-malignant question for follicular nodules. Your team can tell you whether a repeat would add any information in your specific situation.

What is molecular testing and should I ask for it?

Molecular testing analyses the DNA or RNA of the cells collected in your biopsy for changes associated with thyroid cancer. It can reclassify some Category 4 nodules as lower risk, giving some patients and their doctors confidence to monitor rather than operate. It is not universally available at every centre, and its interpretation requires experience. Ask your treating endocrinologist or oncologist whether it is available for your case and whether it is likely to change the recommendation.

Full index

Browse all 701 biopsy topics

Every page in this section, grouped by the part of the journey it belongs to. Pick a group to see what is in it.

What Is a Biopsy?

What Is a Biopsy? Everything You Need to Know →

Types of Biopsy Compared

Which Biopsy Will You Have? Techniques Compared →

Preparing for a Biopsy

What to Expect on the Day of Your Biopsy →

Recovery and Aftercare

After a Biopsy: Recovery, Aftercare and Warning Signs →

Biopsy by Body Part

Biopsy by Body Part: What to Expect at Each Site →

Understanding Your Report

How to Read a Biopsy Report: Terms Explained →

IHC and Molecular Markers

IHC and Molecular Markers on a Biopsy: What They Mean →

Grading and Scoring Systems

Cytology & Prostate Scoring Systems Explained →

How Accurate Is a Biopsy?

How Accurate Is a Biopsy? Errors and Second Opinions →

If Your Result Is Benign

Your Biopsy Is Benign: What It Means and What Comes Next →

Call now Book free consultation